Slpi - secretory leukocyte peptidase inhibitor

Predicted to enable enzyme binding activity; nucleic acid binding activity; and serine-type endopeptidase inhibitor activity. Involved in negative regulation of inflammatory response. Predicted to be located in Golgi apparatus. Predicted to be active in extracellular space. Biomarker of chronic obstructive pulmonary disease; endophthalmitis; middle cerebral artery infarction; myocardial infarction; and polycystic ovary syndrome. Orthologous to human SLPI (secretory leukocyte peptidase inhibitor). [provided by Alliance of Genome Resources, Apr 2022]